Form 4 for BBOT BridgeBio Oncology Therapeutics, Inc.
Accepted 2024-02-13 00:00:00 ET · period of report 2024-02-13 · accession 0001213900-24-013530 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-02-13 | 2024-02-13 | BBOT | Helix Holdings II LLC | Dir, 10% | A - Grant | $10.00 | +509.0K | 509.0K | New | +$5.09M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Ordinary Shares | 2024-02-13 | A | A | 509,000 | $10.00 | 509,000 | I See Footnote | — | — | (F1) Helix Holdings II LLC is the record holder of the securities reported herein. Cormorant Private Healthcare Fund III, LP, a Delaware limited partnership, Cormorant Private Healthcare Fund V, LP, a Delaware limited partnership, and Cormorant Global Healthcare Master Fund, LP, a Cayman Islands limited partnership, are the managing members of Helix Holdings II LLC. Bihua Chen is the manager of Helix Holdings II LLC and is the managing member of each of the three members of Helix Holdings II LLC and has voting and investment discretion with respect to the ordinary shares held of record by Helix Holdings II LLC. Ms. Chen disclaims any beneficial ownership of the securities held by Helix Holdings II LLC other than to the extent of any pecuniary interest she may have therein, directly or indirectly. |